Sarah Anderson
Sarah Anderson is the oncology strategy lead director for Novotech.
Articles
February 3rd 2025
Advancing Triple-Negative Breast Cancer Research in the Asia-Pacific Region
Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer research in the Asia-Pacific region, and the importance of clinical trial diversity in this region.
January 27th 2025
The Current State of Triple-Negative Breast Cancer Trials
Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer clinical trials in the Asia-Pacific region, and the significant investments being made with novel biomarkers.
Latest Updated Articles
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
